Modelling the Cost-Effectiveness of Hepatitis A in South Africa

被引:1
|
作者
Patterson, Jenna [1 ,2 ]
Cleary, Susan [3 ]
Norman, Jared Michael [4 ]
Van Zyl, Heiletje [4 ]
Awine, Timothy [4 ]
Mayet, Saadiyah [4 ]
Kagina, Benjamin [1 ,2 ]
Muloiwa, Rudzani [5 ]
Hussey, Gregory [1 ,2 ]
Silal, Sheetal Prakash [4 ,6 ]
机构
[1] Univ Cape Town, Sch Publ Hlth, Vaccines Africa Initiat, ZA-7925 Cape Town, South Africa
[2] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Sch Publ Hlth, ZA-7925 Cape Town, South Africa
[4] Univ Cape Town, Dept Stat Sci, Modelling & Simulat Hub, Africa MASHA, ZA-7700 Cape Town, South Africa
[5] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, ZA-7700 Cape Town, South Africa
[6] Univ Oxford, Ctr Global Hlth, Nuffield Dept Med, Oxford OX3 7LG, England
基金
新加坡国家研究基金会;
关键词
hepatitis A vaccine; mathematical model; cost-effectiveness; CHRONIC LIVER-FAILURE; EPIDEMIOLOGIC TRANSITION; UNIVERSAL VACCINATION; ARGENTINA; CHILDREN; VIRUS;
D O I
10.3390/vaccines12020116
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The World Health Organization (WHO) recommends the consideration of introducing routine hepatitis A vaccination into national immunization schedules for children >= 1 years old in countries with intermediate HAV endemicity. Recent data suggest that South Africa is transitioning from high to intermediate HAV endemicity, thus it is important to consider the impact and cost of potential routine hepatitis A vaccination strategies in the country. An age-structured compartmental model of hepatitis A transmission was calibrated with available data from South Africa, incorporating direct costs of hepatitis A treatment and vaccination. We used the calibrated model to evaluate the impact and costs of several childhood hepatitis A vaccination scenarios from 2023 to 2030. We assessed how each scenario impacted the burden of hepatitis A (symptomatic hepatitis A cases and mortality) as well as calculated the incremental cost per DALY averted as compared to the South African cost-effectiveness threshold. All costs and outcomes were discounted at 5%. For the modelled scenarios, the median estimated cost of the different vaccination strategies ranged from USD 1.71 billion to USD 2.85 billion over the period of 2023 to 2030, with the cost increasing for each successive scenario and approximately 39-52% of costs being due to vaccination. Scenario 1, which represented the administration of one dose of the hepatitis A vaccine in children < 2 years old, requires approximately 5.3 million vaccine doses over 2023-2030 and is projected to avert a total of 136,042 symptomatic cases [IQR: 88,842-221,483] and 31,106 [IQR: 22,975-36,742] deaths due to hepatitis A over the period of 2023 to 2030. The model projects that Scenario 1 would avert 8741 DALYs over the period of 2023 to 2030; however, it is not cost-effective against the South African cost-effectiveness threshold with an ICER per DALY averted of USD 21,006. While Scenario 3 and 4 included the administration of more vaccine doses and averted more symptomatic cases of hepatitis A, these scenarios were absolutely dominated owing to the population being infected before vaccination through the mass campaigns at older ages. The model was highly sensitive to variation of access to liver transplant in South Africa. When increasing the access to liver transplant to 100% for the baseline and Scenario 1, the ICER for Scenario 1 becomes cost-effective against the CET (ICER = USD 2425). Given these findings, we recommend further research is conducted to understand the access to liver transplants in South Africa and better estimate the cost of liver transplant care for hepatitis A patients. The modelling presented in this paper has been used to develop a user-friendly application for vaccine policy makers to further interrogate the model outcomes and consider the costs and benefits of introducing routine hepatitis A vaccination in South Africa.
引用
收藏
页数:16
相关论文
共 50 条
  • [11] THE COST-EFFECTIVENESS OF SELECTIVE TOBACCO CONTROL POLICIES IN SOUTH AFRICA
    Bitton, Asaf
    Gaziano, Thomas
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 : S353 - S354
  • [12] The cost-effectiveness of alternative polio immunization policies in South Africa
    Griffiths, Ua K.
    Botham, Lindsay
    Schoub, Barry D.
    VACCINE, 2006, 24 (29-30) : 5670 - 5678
  • [13] Cost-effectiveness of highly active antiretroviral therapy in South Africa
    Badri, M
    Maartens, G
    Mandalia, S
    Bekker, LG
    Penrod, JR
    Platt, RW
    Wood, R
    Beck, EJ
    PLOS MEDICINE, 2006, 3 (01) : 48 - 56
  • [14] Cost-effectiveness in hepatitis B
    Weitzman, G
    Jacobson, I
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (10) : 757 - 758
  • [15] Modelling cost-effectiveness in osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    BONE, 2008, 43 (01) : 215 - 216
  • [16] Modelling for cost-effectiveness analysis
    Russell, LB
    STATISTICS IN MEDICINE, 1999, 18 (23) : 3235 - 3244
  • [17] Treatment of hepatitis C in prison: cost-effectiveness demonstrated by mathematical modelling
    Watson, K. J. R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A330 - A330
  • [18] Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits
    Scott, Nick
    Win, Thin Mar
    Tidhar, Tom
    Htay, Hla
    Draper, Bridget
    Aung, Phyo Thu Zar
    Xiao, Yinzong
    Bowring, Anna
    Kuschel, Christian
    Shilton, Sonjelle
    Kyi, Khin Pyone
    Naing, Win
    Aung, Khin Sanda
    Hellard, Margaret
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2021, 10
  • [19] The Case for Adolescent HIV Vaccination in South Africa A Cost-Effectiveness Analysis
    Moodley, Nishila
    Gray, Glenda
    Bertram, Melanie
    MEDICINE, 2016, 95 (04)
  • [20] Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis
    Elisa F. Long
    Robert R. Stavert
    Journal of General Internal Medicine, 2013, 28 : 1294 - 1301